EUR 0.22
(-2.61%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 32.66 Million EUR | -2.6% |
2022 | 30.41 Million EUR | -8.93% |
2021 | 33.4 Million EUR | 13.89% |
2020 | 29.32 Million EUR | -5.39% |
2019 | 30.99 Million EUR | -6.19% |
2018 | 33.04 Million EUR | 37.75% |
2017 | 23.98 Million EUR | 8.95% |
2016 | 22.01 Million EUR | 61.18% |
2015 | 13.66 Million EUR | 102.59% |
2014 | 6.74 Million EUR | 137.57% |
2013 | 2.83 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 4.56 Million EUR | -28.1% |
2024 Q2 | 4.56 Million EUR | 0.0% |
2023 Q3 | 6.34 Million EUR | -67.12% |
2023 Q1 | 6.66 Million EUR | -15.62% |
2023 Q4 | 6.34 Million EUR | 0.0% |
2023 FY | 29.62 Million EUR | -2.6% |
2023 Q2 | 19.31 Million EUR | 189.72% |
2022 Q4 | 7.9 Million EUR | 0.0% |
2022 Q3 | 7.9 Million EUR | -50.03% |
2022 Q1 | 7.01 Million EUR | -30.13% |
2022 Q2 | 15.81 Million EUR | 125.37% |
2022 FY | 30.41 Million EUR | -8.93% |
2021 FY | 33.4 Million EUR | 13.89% |
2021 Q2 | 13.17 Million EUR | 87.2% |
2021 Q4 | 10.04 Million EUR | 0.0% |
2021 Q1 | 7.03 Million EUR | -53.2% |
2021 Q3 | 10.04 Million EUR | -23.76% |
2020 Q2 | 16.41 Million EUR | 90.65% |
2020 Q3 | 11.25 Million EUR | -31.4% |
2020 Q4 | 15.03 Million EUR | 33.54% |
2020 FY | 29.32 Million EUR | -5.39% |
2020 Q1 | 8.6 Million EUR | -43.17% |
2019 Q3 | 7.84 Million EUR | -58.85% |
2019 Q2 | 19.07 Million EUR | 93.96% |
2019 Q1 | 9.83 Million EUR | -58.83% |
2019 FY | 30.99 Million EUR | -6.19% |
2019 Q4 | 15.14 Million EUR | 92.99% |
2018 Q1 | 6.65 Million EUR | -14.98% |
2018 Q3 | 12.04 Million EUR | -8.72% |
2018 Q4 | 23.88 Million EUR | 98.39% |
2018 FY | 33.04 Million EUR | 37.75% |
2018 Q2 | 13.19 Million EUR | 98.18% |
2017 Q4 | 7.82 Million EUR | 0.0% |
2017 Q1 | 6.04 Million EUR | -12.93% |
2017 FY | 23.98 Million EUR | 8.95% |
2017 Q2 | 6.04 Million EUR | 0.0% |
2017 Q3 | 7.82 Million EUR | 29.58% |
2016 Q1 | 5.59 Million EUR | 3.04% |
2016 Q3 | 6.93 Million EUR | 24.04% |
2016 Q2 | 5.59 Million EUR | 0.0% |
2016 Q4 | 6.93 Million EUR | 0.0% |
2016 FY | 22.01 Million EUR | 61.18% |
2015 Q3 | 5.38 Million EUR | 67.62% |
2015 Q4 | 5.42 Million EUR | 0.77% |
2015 FY | 13.66 Million EUR | 102.59% |
2015 Q2 | 3.21 Million EUR | 0.0% |
2015 Q1 | 3.21 Million EUR | 38.2% |
2014 Q4 | 2.32 Million EUR | 0.0% |
2014 FY | 6.74 Million EUR | 137.57% |
2014 Q1 | 1.56 Million EUR | 0.0% |
2014 Q3 | 2.32 Million EUR | 48.97% |
2014 Q2 | 1.56 Million EUR | 0.0% |
2013 FY | 2.83 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -681.901% |
ABIVAX Société Anonyme | 127.37 Million EUR | 74.359% |
Adocia SA | 15.62 Million EUR | -108.971% |
Aelis Farma SA | 18.81 Million EUR | -73.548% |
Biophytis S.A. | 14.33 Million EUR | -127.866% |
Advicenne S.A. | 8.21 Million EUR | -297.565% |
genOway Société anonyme | 16.73 Million EUR | -95.122% |
IntegraGen SA | 5.35 Million EUR | -510.181% |
Medesis Pharma S.A. | 1.56 Million EUR | -1987.472% |
Neovacs S.A. | 10.34 Million EUR | -215.752% |
NFL Biosciences SA | 4.37 Million EUR | -646.625% |
Plant Advanced Technologies SA | 2.76 Million EUR | -1081.258% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -1801.086% |
Sensorion SA | 27.05 Million EUR | -20.723% |
Theranexus Société Anonyme | 3 Million EUR | -986.86% |
TME Pharma N.V. | 5.49 Million EUR | -494.142% |
Valbiotis SA | 9.86 Million EUR | -230.935% |
TheraVet SA | 1.64 Million EUR | -1886.24% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -60.728% |
DBV Technologies S.A. | 89.4 Million EUR | 63.47% |
Genfit S.A. | 54.8 Million EUR | 40.406% |
GeNeuro SA | 14.35 Million EUR | -127.48% |
Innate Pharma S.A. | 64.57 Million EUR | 49.419% |
Inventiva S.A. | 120.18 Million EUR | 72.825% |
MaaT Pharma SA | 21.59 Million EUR | -51.218% |
MedinCell S.A. | 32.92 Million EUR | 0.796% |
Nanobiotix S.A. | 58.92 Million EUR | 44.575% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -38.454% |
Poxel S.A. | 28.76 Million EUR | -13.541% |
Transgene SA | 31.23 Million EUR | -4.576% |
Valneva SE | 134.92 Million EUR | 75.794% |